Skip to main content
OpenTrials
Completed

NCT Number: NCT02235259

Efficacy and Safety of XG-104 for the Treatment of Dry Eye

The objective of this study is to assess the safety and efficacy of XG-104 Ophthalmic Solution compared to placebo for the treatment of the signs and symptoms of dry eye after a 4 week Three Times a Day (TID) treatment period

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Andover Eye Associates

Andover, Massachusetts, 01810, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be at least 18 years of age
  • Provide written informed consent
  • Have a subject reported history of dry eye
  • Have a history of use or desire to use eye drops

Exclusion criteria

  • Have any clinically significant eye findings that require therapeutic treatment, and/or in the opinion of the Investigator may interfere with study parameters;
  • Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study;
  • Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;
  • Have used Restasis® within 30 days of Visit 1;
  • Have any planned ocular and/or lid surgeries over the study period;
  • Be a woman who is pregnant, nursing or planning a pregnancy;
  • Be unwilling to submit a urine pregnancy test at Visit 1 and Visit 4 (or early termination visit) if of childbearing potential.
  • Have a known allergy and/or sensitivity to the study drug or its components
  • Have a condition or be in a situation which the Investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study;
  • Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days of Visit 1;
  • Be unable or unwilling to follow instructions, including participation in all study assessments and visits

Treatment and study plan

XG-104

Drug

Comparison of XG-104 (3 concentrations) versus placebo eye drops efficacy

Placebo

Drug

Primary outcomes

  1. Corneal Fluorescein Staining: in the inferior region change from Pre-CAESM to Post- CAESM, as measured by the Ora CalibraTM Scale

    Time frame: Day 29

  2. Worst Dry Eye Symptom

    Time frame: From D22 to Day 28

Secondary outcomes

  1. Fluorescein Staining using Ora Calibra™ Scale and NEI Scale (all régions) Pre- and Post-CAESM

    Time frame: Day 15

  2. Fluorescein Staining using Ora Calibra™ Scale and NEI Scale (all régions) Pre- and Post-CAESM

    Time frame: Day 29

  3. Lissamine Green Staining using Ora Calibra™ Scale and NEI Scale (all regions) (Pre- and Post-CAESM and change from Pre- to Post-CAESM

    Time frame: Day 15

  4. Lissamine Green Staining using Ora Calibra™ Scale and NEI Scale (all regions) (Pre- and Post-CAESM and change from Pre- to Post-CAESM

    Time frame: Day 29

  5. Tear Film Break-up Time (Pre- and Post-CAESM)

    Time frame: Day 15

  6. Tear Film Break-up Time (Pre- and Post-CAESM)

    Time frame: Day 29

  7. Conjunctival Redness using Ora Calibra™ Scale (Pre- and Post-CAESM)

    Time frame: Day 15

  8. Conjunctival Redness using Ora Calibra™ Scale (Pre- and Post-CAESM)

    Time frame: Day 29

  9. Lid Margin Redness using Ora Calibra scale (Pre- and Post-CAESM)

    Time frame: Day 15

  10. Lid Margin Redness using Ora Calibra scale (Pre- and Post-CAESM)

    Time frame: Day 29

  11. Tear Osmolarity (Post-CAESM)

    Time frame: Day 1

  12. Tear Osmolarity (Post-CAESM)

    Time frame: Day 29

  13. Blink Rate (Pre-CAESM ) using Ora Calibra™ Methodology

    Time frame: Day 15

  14. Blink Rate (Pre-CAESM ) using Ora Calibra™ Methodology

    Time frame: Day 29

  15. Ocular Protection Index (OPI 2.0) (Pre-CAESM ) using Ora Calibra™ Methodology

    Time frame: Day 15

  16. Ocular Protection Index (OPI 2.0) (Pre-CAESM ) using Ora Calibra™ Methodology

    Time frame: Day 29

  17. Unanesthetized Schirmer's Test (Pre-CAESM)

    Time frame: Day 15

  18. Unanesthetized Schirmer's Test (Pre-CAESM)

    Time frame: Day 29

  19. Drop Comfort and Symptom Assessment using Ora Calibra™ Scales

    Time frame: Day 1

  20. Drop Comfort and Symptom Assessment using Ora Calibra™ Scales

    Time frame: Day 15

  21. Ocular Surface Disease Index (OSDI) (Pre-CAESM)

    Time frame: Day 15

  22. Ocular Surface Disease Index (OSDI) (Pre-CAESM)

    Time frame: Day 29

  23. Ocular Discomfort using Ora Calibra™ Scale (Pre and Post-CAESM)

    Time frame: Day 15

  24. Ocular Discomfort using Ora Calibra™ Scale (Pre and Post-CAESM)

    Time frame: Day 29

  25. Ocular Discomfort using Ora Calibra™ Discomfort and 4-Symptom Questionnaire (Pre and Post-CAESM)

    Time frame: Day 15

  26. Ocular Discomfort using Ora Calibra™ Discomfort and 4-Symptom Questionnaire (Pre and Post-CAESM)

    Time frame: Day 29

  27. Ocular Discomfort using Ora Calibra™ Scale (during CAESM exposure)

    Time frame: Day 15

  28. Ocular Discomfort using Ora Calibra™ Scale (during CAESM exposure)

    Time frame: Day 29

  29. Daily diary

    Time frame: up to Day 29

Other outcomes

  1. Visual Acuity (ETDRS) (Pre-CAESM)

    Time frame: Day -7

  2. Visual Acuity (ETDRS) (Pre-CAESM)

    Time frame: Day 1

  3. Visual Acuity (ETDRS) (Pre-CAESM)

    Time frame: Day 15

  4. Visual Acuity (ETDRS) (Pre-CAESM)

    Time frame: Day 29

  5. Slit-Lamp Biomicroscopy (Pre- and Post-CAESM)

    Time frame: Day -7

  6. Slit-Lamp Biomicroscopy (Pre- and Post-CAESM)

    Time frame: Day 1

  7. Slit-Lamp Biomicroscopy (Pre- and Post-CAESM)

    Time frame: Day 15

  8. Slit-Lamp Biomicroscopy (Pre- and Post-CAESM)

    Time frame: Day 29

  9. Adverse event query

    Time frame: up to Day 29

  10. Dilated Fundoscopy Biomicroscopy

    Time frame: Day -7

  11. Dilated Fundoscopy Biomicroscopy

    Time frame: Day 29

  12. Intraocular Pressure

    Time frame: Day -7

  13. Intraocular Pressure

    Time frame: Day 29

Sponsors and collaborators

Lead sponsor

Xigen SA

Industry

Registry information

Official study title

A Phase II, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of XG-104 Ophthalmic Solutions in the Environment, and During Challenge in the Controlled Adverse Environmental (CAESM ) Model for the Treatment of Dry Eye

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Sep 9, 2014
Registry last updated
Jul 18, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.